379 related articles for article (PubMed ID: 23356585)
1. Hsp90, an unlikely ally in the war on cancer.
Barrott JJ; Haystead TA
FEBS J; 2013 Mar; 280(6):1381-96. PubMed ID: 23356585
[TBL] [Abstract][Full Text] [Related]
2. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
Lu X; Xiao L; Wang L; Ruden DM
Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
[TBL] [Abstract][Full Text] [Related]
5. Associations of HSP90 client proteins in human breast cancer.
Shipp C; Watson K; Jones GL
Anticancer Res; 2011 Jun; 31(6):2095-101. PubMed ID: 21737627
[TBL] [Abstract][Full Text] [Related]
6. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
7. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
[TBL] [Abstract][Full Text] [Related]
8. Targeting HSP90 Gene Expression with 17-DMAG Nanoparticles in Breast Cancer Cells.
Mellatyar H; Talaei S; Nejati-Koshki K; Akbarzadeh A
Asian Pac J Cancer Prev; 2016; 17(5):2453-7. PubMed ID: 27268613
[TBL] [Abstract][Full Text] [Related]
9. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
12. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
Arteaga CL
Clin Cancer Res; 2011 Aug; 17(15):4919-21. PubMed ID: 21670086
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
14. Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone.
Miyata Y; Nishida E
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119081. PubMed ID: 34147560
[TBL] [Abstract][Full Text] [Related]
15. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
16. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.
Laederich MB; Degnin CR; Lunstrum GP; Holden P; Horton WA
J Biol Chem; 2011 Jun; 286(22):19597-604. PubMed ID: 21487019
[TBL] [Abstract][Full Text] [Related]
18. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
Zajac M; Gomez G; Benitez J; Martínez-Delgado B
BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
20. UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition.
Sultana R; Theodoraki MA; Caplan AJ
Exp Cell Res; 2012 Jan; 318(1):53-60. PubMed ID: 21983172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
